430 related articles for article (PubMed ID: 17637212)
1. Factors affecting the health-related quality of life of patients with cervical dystonia and the impact of botulinum toxin type A injections.
Slawek J; Friedman A; Potulska A; Krystkowiak P; Gervais C; Banach M; Ochudlo S; Budrewicz S; Reclawowicz D; Rynkowski M; Opala G
Funct Neurol; 2007; 22(2):95-100. PubMed ID: 17637212
[TBL] [Abstract][Full Text] [Related]
2. The impact of blepharospasm and cervical dystonia on health-related quality of life and depression.
Müller J; Kemmler G; Wissel J; Schneider A; Voller B; Grossmann J; Diez J; Homann N; Wenning GK; Schnider P; Poewe W;
J Neurol; 2002 Jul; 249(7):842-6. PubMed ID: 12140667
[TBL] [Abstract][Full Text] [Related]
3. A prospective, randomized, double-blind study comparing the efficacy and safety of type a botulinum toxins botox and prosigne in the treatment of cervical dystonia.
Quagliato EM; Carelli EF; Viana MA
Clin Neuropharmacol; 2010; 33(1):22-6. PubMed ID: 19959960
[TBL] [Abstract][Full Text] [Related]
4. Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia.
Truong D; Brodsky M; Lew M; Brashear A; Jankovic J; Molho E; Orlova O; Timerbaeva S;
Parkinsonism Relat Disord; 2010 Jun; 16(5):316-23. PubMed ID: 20359934
[TBL] [Abstract][Full Text] [Related]
5. BotB (botulinum toxin type B): evaluation of safety and tolerability in botulinum toxin type A-resistant cervical dystonia patients (preliminary study).
Truong DD; Cullis PA; O'Brien CF; Koller M; Villegas TP; Wallace JD
Mov Disord; 1997 Sep; 12(5):772-5. PubMed ID: 9380065
[TBL] [Abstract][Full Text] [Related]
6. CDIP-58 can measure the impact of botulinum toxin treatment in cervical dystonia.
Cano SJ; Hobart JC; Edwards M; Fitzpatrick R; Bhatia K; Thompson AJ; Warner TT
Neurology; 2006 Dec; 67(12):2230-2. PubMed ID: 17190951
[TBL] [Abstract][Full Text] [Related]
7. Comparison of clinical rating scales in treatment of cervical dystonia with botulinum toxin.
Tarsy D
Mov Disord; 1997 Jan; 12(1):100-2. PubMed ID: 8990061
[TBL] [Abstract][Full Text] [Related]
8. Botulinum toxin and neuromotor rehabilitation: An integrated approach to idiopathic cervical dystonia.
Tassorelli C; Mancini F; Balloni L; Pacchetti C; Sandrini G; Nappi G; Martignoni E
Mov Disord; 2006 Dec; 21(12):2240-3. PubMed ID: 17029278
[TBL] [Abstract][Full Text] [Related]
9. A pilot study of botulinum toxin A for headache in cervical dystonia.
Ondo WG; Gollomp S; Galvez-Jimenez N
Headache; 2005 Sep; 45(8):1073-7. PubMed ID: 16109123
[TBL] [Abstract][Full Text] [Related]
10. Long-term follow-up of cervical dystonia patients treated with botulinum toxin A.
Haussermann P; Marczoch S; Klinger C; Landgrebe M; Conrad B; Ceballos-Baumann A
Mov Disord; 2004 Mar; 19(3):303-8. PubMed ID: 15022184
[TBL] [Abstract][Full Text] [Related]
11. Fast voluntary neck movements in patients with cervical dystonia: a kinematic study before and after therapy with botulinum toxin type A.
Gregori B; Agostino R; Bologna M; Dinapoli L; Colosimo C; Accornero N; Berardelli A
Clin Neurophysiol; 2008 Feb; 119(2):273-80. PubMed ID: 18063411
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic use of botulinum toxin type A in treating neck and upper-back pain of myofascial origin: a pilot study.
Lew HL; Lee EH; Castaneda A; Klima R; Date E
Arch Phys Med Rehabil; 2008 Jan; 89(1):75-80. PubMed ID: 18164334
[TBL] [Abstract][Full Text] [Related]
13. Improvement in quality of life after botulinum toxin-A injections for idiopathic detrusor overactivity: results from a randomized double-blind placebo-controlled trial.
Sahai A; Dowson C; Khan MS; Dasgupta P
BJU Int; 2009 Jun; 103(11):1509-15. PubMed ID: 19389019
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of repeated doses of botulinum toxin type B in type A resistant and responsive cervical dystonia.
Factor SA; Molho ES; Evans S; Feustel PJ
Mov Disord; 2005 Sep; 20(9):1152-60. PubMed ID: 15954134
[TBL] [Abstract][Full Text] [Related]
15. Botulinum toxin improves the quality of life and reduces the intensification of depressive symptoms in patients with blepharospasm.
Ochudlo S; Bryniarski P; Opala G
Parkinsonism Relat Disord; 2007 Dec; 13(8):505-8. PubMed ID: 17543569
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study.
Truong D; Duane DD; Jankovic J; Singer C; Seeberger LC; Comella CL; Lew MF; Rodnitzky RL; Danisi FO; Sutton JP; Charles PD; Hauser RA; Sheean GL
Mov Disord; 2005 Jul; 20(7):783-91. PubMed ID: 15736159
[TBL] [Abstract][Full Text] [Related]
17. Safety, effectiveness, and duration of effect of BOTOX after switching from Dysport for blepharospasm, cervical dystonia, and hemifacial spasm dystonia, and hemifacial spasm.
Bihari K
Curr Med Res Opin; 2005 Mar; 21(3):433-8. PubMed ID: 15811212
[TBL] [Abstract][Full Text] [Related]
18. Psychosocial aspects of patients with focal hyperhidrosis. Marked reduction of social phobia, anxiety and depression and increased quality of life after treatment with botulinum toxin A.
Weber A; Heger S; Sinkgraven R; Heckmann M; Elsner P; Rzany B
Br J Dermatol; 2005 Feb; 152(2):342-5. PubMed ID: 15727649
[TBL] [Abstract][Full Text] [Related]
19. Determinants and status of quality of life after long-term botulinum toxin therapy for cervical dystonia.
Skogseid IM; Malt UF; Røislien J; Kerty E
Eur J Neurol; 2007 Oct; 14(10):1129-37. PubMed ID: 17708754
[TBL] [Abstract][Full Text] [Related]
20. The Canadian multicentre study of deep brain stimulation for cervical dystonia.
Kiss ZH; Doig-Beyaert K; Eliasziw M; Tsui J; Haffenden A; Suchowersky O; ;
Brain; 2007 Nov; 130(Pt 11):2879-86. PubMed ID: 17905796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
